Orphan Drugs

AbbVie makes inroads in orphan drugs

AbbVie makes inroads in orphan drugs

By

Not long after acquiring Shire to add to its orphan-drug portfolio, the drugmaker scored an orphan designation from both FDA and EMA last week.

Biotech Report: Ultra Man

Biotech Report: Ultra Man

By

Innovation is still valued in the orphan-drug space, but the reimbursement bar is rising. NPS Pharma's Eric Pauwels, who's launched five ultra-rare disease products, explains how these biotech brands can demonstrate their value. Marc Iskowitz reports

Sanofi seeks to revive Kynamro launch

Sanofi seeks to revive Kynamro launch

By

Kynamro's slow start, coupled with competition, has prompted Sanofi to add sales reps.

Rare diseases may be less so

Regulatory Focus discusses how the expanding US population may make it harder for a condition to qualify as rare.

Dept. of Justice subpoenas Aegerion

Dept. of Justice subpoenas Aegerion

By

The drugmaker announced Friday that the DOJ wants documents regarding sales and marketing of Juxtapid, its drug for an ultra-rare lipid disorder.

Company news: Burson-Marsteller, Corcept and Orexigen

PR firm Burson-Marsteller launched a new healthcare subsidiary, Orexigen's net loss widened in Q2, and Corcept closed out its first full quarter with orphan treatment Korlym.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.